Complement System
The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.
The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.
All Product Categories
-
Complement System Inhibitors
(134)
View all products
-
Complement System Agonists
(13)
View all products
-
Complement System Antagonists
(21)
View all products
-
Complement System Activators
(7)
View all products
-
Complement System Modulator
(1)
View all products
-
Complement System Controls
(2)
View all products
-
Complement System Ligands
(3)
View all products
-
Complement System Proteins
(113)
View all products
-
Complement System Verwandte Produkte (212)
Verwandte Produkte (212)
-
Recombinant Proteins (113)
-
Antibodies (7)
-
CK3 peptide
0 ImagesArt. -Nr.: HY-P10788CAS. Nr.: 1801552-75-9CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.
-
Campneoside II
0 ImagesArt. -Nr.: HY-N10400CAS. Nr.: 95587-86-3Campneoside II is a compound isolated from Paulownia tomentosa var. tomentosa wood. Campneoside II exhibits excellent anti-complement activity.
-
Factor B-IN-4
0 ImagesArt. -Nr.: HY-147606CAS. Nr.: 2760669-84-7Factor B-IN-4 (Example 13 target compound) is a potent complement factor B inhibitor, with an IC50 of 1 μM. Factor B-IN-4 can be used for the research of diseases related to inflammation and immunity.
-
Factor B-IN-7
0 ImagesArt. -Nr.: HY-178284Factor B-IN-7 (Compound (I)) is a selective Factor B inhibitor. Factor B-IN-7 inhibits Factor B-C3b interaction to suppress complement hyperactivation. Factor B-IN-7 is promising for research of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD) associated with complement-mediated diseases.
-
C5aR1 antagonist 1
0 ImagesArt. -Nr.: HY-163378CAS. Nr.: 2365325-67-1C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC50 values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases.
-
VIR-2482
0 ImagesArt. -Nr.: HY-P992482VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease.
-
Cyclosporin A-KLH
0 ImagesArt. -Nr.: HY-NP194BCyclosporin A-KLH is a conjugate of Cyclosporin A (HY-B0579) and KLH. Cyclosporin A is an immunosuppressant which binds to the cyclophilin .
-
BuChE-IN-23
0 ImagesArt. -Nr.: HY-183352CAS. Nr.: 3067571-93-8BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC50 of 15.59 μM and a Ki of 29.33 μM. BuChE-IN-23 exhibits an IC50 of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease.
-
Avacopan-d4
0 ImagesArt. -Nr.: HY-17627S1CAS. Nr.: 2316781-85-6Synonyms: CCX168-d4
-
[DArg10, DAla20] TLQP-21
![[DArg10, DAla20] TLQP-21](https://file.medchemexpress.com/product_pic/hy-p1345b.gif "Click to View [DArg10, DAla20] TLQP-21 Product Detail")
0 ImagesArt. -Nr.: HY-P1345B[DArg10, DAla20] TLQP-21, TLQP-21 (HY-P1345) analogue, is a C3aR agonist (EC50: 87 nM for β-arrestin recruitment). [DArg10, DAla20] TLQP-21 elicits calcium influx. [DArg10, DAla20] TLQP-21 slightly but not significantly potentiates adrenergic-induced lipolysis. [DArg10, DAla20] TLQP-21 can be used in the research of inflammatory diseases, metabolic disorders, and neurological conditions.
-
C1q Protein (rabbit)
0 ImagesArt. -Nr.: HY-NP0194BC1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease.
-
Factor B-IN-6
0 ImagesArt. -Nr.: HY-177388CAS. Nr.: 2797066-55-6Factor B-IN-6 is an orally active Factor B inhibitor. Factor B-IN-6 exhibits significant inhibitory activity against activation of the human serum serotonin pathway. Factor B-IN-6 can improve the severity of renal lesions and renal function, and reduce urinary protein in animal models. Factor B-IN-6 is useful for kidney disease research.
-
C5a Anaphylatoxin (human)
0 ImagesArt. -Nr.: HY-P4971CAS. Nr.: 1816940-05-2C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. C5a Anaphylatoxin (human) can be used to study inflammation and immunity, such as allergic asthma.
-
C5aR antagonist-1
0 ImagesArt. -Nr.: HY-183414CAS. Nr.: 1257868-45-3C5aR antagonist-1 is a potent C5aR antagonist with an IC50 of < 5 nM. C5aR antagonist-1 is applicable to the research of crescentic and necrotizing glomerular lesions.
-
Pulchinenoside J
0 ImagesArt. -Nr.: HY-N19128CAS. Nr.: 1476801-10-1Pulchinenoside J is a lupane-type triterpenoid saponin and a complement system inhibitor that acts via the classical pathway. Pulchinenoside J can be isolated from the roots of Pulsatilla chinensis.
-
Zilucoplan TFA
0 ImagesArt. -Nr.: HY-P3502ASynonyms: RA101495 TFA; RA3193 TFAZilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM).
-
TAT-327
0 ImagesArt. -Nr.: HY-P10995TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models.
-
Factor B-IN-5
0 ImagesArt. -Nr.: HY-174913CAS. Nr.: 1644670-23-4Factor B-IN-5 is an orally active complement factor B (CFB) inhibitor. Factor B-IN-5 alleviates kidney damage in diabetes nephropathy by inhibiting the over activation of complement system and improving mitochondrial function. Factor B-IN-5 can improve renal tubulointerstitial inflammation and fibrosis. Factor B-IN-5 can be used for research on diabetic nephropathy.
